Eli Lilly and Co. and Sarah Cannon Research Institute (SCRI) entered a strategic partnership to co‑develop an investigational Phase II oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management.

“Lilly has a long history of leading innovation in cancer therapy with the goal to offer patients improved treatment outcomes,” said Christopher A. Slapak, M.D., vice president, early phase clinical research for Lilly. “This strategic partnership is an exciting step to foster further collaboration with SCRI in advancing the field of cancer research.”

“Our clinical trial management capabilities and scientific leadership, combined with Lilly’s leading drug development expertise, furthers our mission to advance therapies for patients seeking novel cancer medicines,” said Dee Anna Smith, chief executive officer of SCRI. “Through partnerships like this one, we can accelerate the time it takes to bring clinical trials into communities for those fighting cancer.”